<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351533</url>
  </required_header>
  <id_info>
    <org_study_id>28503-A</org_study_id>
    <secondary_id>05-7895-A 03</secondary_id>
    <nct_id>NCT00351533</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)</brief_title>
  <official_title>A Randomized, Double-blind Study of the Effect of Fish Oil (Eicosapentaenoic Acid and Docosahexanoic Acid) on Lung and Systemic Inflammation in Patients With Acute Lung Injury (ALI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Thoracic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Acute Respiratory Distress Syndrome Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Society for Parenteral and Enteral Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids)
      given enterally is safe and effective in reducing lung and systemic inflammation seen in
      acute lung injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute lung injury (ALI) is common among critically ill patients and is associated with a high
      case fatality. Only one intervention has been shown to improve survival in a large clinical
      trial, and new therapies targeting the inflammatory response are needed. Nutrient
      interventions may provide benefit; specifically there is plausible biologic rationale for
      administering n-3 fatty acids (n-3 FAs) found in fish oil to patients with ALI, as n-3 FAs
      decrease formation of eicosanoid inflammatory mediators. However, although promising results
      have emerged from prior studies, fish oils have only been tested in ALI patients in a
      commercial enteral formula containing additional nutrients, and the control group received a
      high-fat enteral formula that may have been proinflammatory. Therefore, no conclusion can be
      drawn about the independent effect of fish oils. Furthermore, the inclusion of key
      pharmaconutrients in feeding formulas, instead of delivering them separately as
      pharmaceuticals, limits exposure to the agent, as intensive care unit (ICU) patients commonly
      receive less than 60% of prescribed caloric needs. Finally, specialized feeding formulas are
      very expensive, and it may be substantially cheaper to administer pharmaconutrients
      separately. We believe it is time to begin to approach nutrient trials in critically ill
      patients differently -- to move away from including them in feeding formulas and begin
      delivering them like pharmaceuticals. With appropriate scientific investigation and the use
      of non-nutrient placebos, this novel and innovative approach is a new paradigm of
      investigating nutrient delivery to critically ill patients.

      This study is a phase II randomized controlled trial to determine the effects of enteral
      eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), both n-3 FAs found in fish oil,
      versus placebo on the pulmonary and systemic environments, and on clinical outcomes, in
      patients with ALI. We will investigate the effect of fish oil administration on several
      biological markers of injury and inflammation in bronchoalveolar lavage fluid and serum, on
      pulmonary physiologic outcomes, and on clinical outcomes.

      Comparison(s): Mechanically ventilated patients with acute lung injury randomized to receive
      enteral fish oil versus compared to mechanically ventilated patients with acute lung injury
      randomized to receive placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Leukotriene B4</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Interleukin-6</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Monocyte Chemotactic Protein-1</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Neutrophil Count</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static Lung Compliance</measure>
    <time_frame>Day 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Day 5</time_frame>
    <description>PaO2/FiO2 is the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen. 30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Interleukin-8</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Leukotriene B4</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Interleukin-6</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Surfactant Protein D</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma vonWillebrand Factor</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Multiple Organ Dysfunction Score (MODS) During First 28 Days After Study Enrollment</measure>
    <time_frame>Throughout hospital stay</time_frame>
    <description>Full scale name is Multiple Organ Dysfunction Score (MODS), a scale measuring degree of organ dysfunction in critically ill patients.
Minimum score is 0 and maximum score is 24, with 0 indicating no organ failure and 24 indicating severe failure of multiple organs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days During First 28 Days After Study Enrollment</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days is a common outcome measure in critical care research. A ventilator-free day is a day that a participant is alive and not receiving mechanical ventilation during the first 28 days after s/he enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free Days During First 28 Days After Study Enrollment</measure>
    <time_frame>28 days</time_frame>
    <description>ICU-free days is a common outcome measure in critical care research. An ICU-free day is a day that a participant is alive and not in the intensive care unit (ICU) during the first 28 days after s/he enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>At end of hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>At end of hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-day Mortality</measure>
    <time_frame>60 days from day of enrollment into study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Leukotriene B4</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Interleukin-6</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Monocyte Chemotactic Protein-1</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BALF Neutrophil Count</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Interleukin-8</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Leukotriene B4</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Interleukin-6</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Surfactant Protein D</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma vonWillebrand Factor</measure>
    <time_frame>Days 1 and 9</time_frame>
    <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Acute Lung Injury</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enteral fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enteral saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil (eicosapentaenoic acid and docosahexanoic acid)</intervention_name>
    <description>Liquid fish oil 7.5cc enterally every 6 hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requiring positive-pressure mechanical ventilation

          -  ALI criteria: PaO2/FiO2 &lt;300, bilateral infiltrates on chest radiograph, no left
             atrial hypertension

          -  Age &gt; 17 years

        Exclusion Criteria:

          -  Expected ICU length of stay &lt;48 hours

          -  Unable to undergo bronchoalveolar lavage at enrollment

          -  Unable to obtain enteral access

          -  Post-cardiac arrest with suspected significant anoxic brain injury

          -  Expected survival &lt; 28 days

          -  Pregnant

          -  Platelet count &lt; 30,000, active bleeding, or international normalized ratio (INR)&gt;3.0

          -  History of ventricular tachycardia or fibrillation

          -  Receiving recombinant human activated protein C (rh-APC) for sepsis

          -  Acquired immune deficiency syndrome (AIDS) with CD4 count &lt; 200

          -  Metastatic cancer

          -  History of bone marrow, lung, liver, cardiac, kidney, or pancreas transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee D. Stapleton, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Alphonsus Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont/Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2006</study_first_posted>
  <results_first_submitted>February 16, 2011</results_first_submitted>
  <results_first_submitted_qc>August 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2011</results_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Renee Stapleton</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Respiratory distress syndrome, adult</keyword>
  <keyword>Acute lung injury</keyword>
  <keyword>Acute respiratory distress syndrome</keyword>
  <keyword>ARDS, human</keyword>
  <keyword>Fish oils</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Docosahexaenoic Acids</keyword>
  <keyword>Eicosapentaenoic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enteral Fish Oil</title>
          <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
        </group>
        <group group_id="P2">
          <title>Enteral Saline</title>
          <description>7.5cc 0.9% saline every 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">Pts did not undergo BALs if not intubated</participants>
                <participants group_id="P2" count="44">Pts did not undergo BALs if not intubated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Extubated before first BAL</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enteral Fish Oil</title>
          <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
        </group>
        <group group_id="B2">
          <title>Enteral Saline</title>
          <description>7.5cc 0.9% saline every 6 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="16.5"/>
                    <measurement group_id="B2" value="50.7" spread="16.5"/>
                    <measurement group_id="B3" value="49.9" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <population>The primary outcome was &gt;=50% reduction in BALF IL-8, measured as the change from baseline to day 5. With α=0.05 and β=0.2, we calculated that 26 patients per group were needed if participants underwent two BALs. Analysis was intention to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <population>The primary outcome was &gt;=50% reduction in BALF IL-8, measured as the change from baseline to day 5. With α=0.05 and β=0.2, we calculated that 26 patients per group were needed if participants underwent two BALs. Analysis was intention to treat (ITT).</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="-656" upper_limit="604"/>
                    <measurement group_id="O2" value="-241" lower_limit="-807" upper_limit="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Leukotriene B4</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Leukotriene B4</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="-1" upper_limit="14"/>
                    <measurement group_id="O2" value="-2" lower_limit="-26" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Interleukin-6</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Interleukin-6</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" lower_limit="-340" upper_limit="51"/>
                    <measurement group_id="O2" value="-200" lower_limit="-692" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Monocyte Chemotactic Protein-1</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Monocyte Chemotactic Protein-1</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-150" lower_limit="-1812" upper_limit="93"/>
                    <measurement group_id="O2" value="-226" lower_limit="-752" upper_limit="-38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Neutrophil Count</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Neutrophil Count</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units># of cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-19" upper_limit="12"/>
                    <measurement group_id="O2" value="-10" lower_limit="-21" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Lung Compliance</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Static Lung Compliance</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
          <units>L/cm H20</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="10.1"/>
                    <measurement group_id="O2" value="36.3" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation</title>
        <description>PaO2/FiO2 is the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen. 30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation</title>
          <description>PaO2/FiO2 is the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen. 30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.</description>
          <units>PaO2/FiO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.4" spread="92.8"/>
                    <measurement group_id="O2" value="174.0" spread="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Interleukin-8</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Interleukin-8</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-8" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-13" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Leukotriene B4</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Leukotriene B4</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="O2" value="-6" lower_limit="-35" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Interleukin-6</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Interleukin-6</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" lower_limit="-162" upper_limit="-13"/>
                    <measurement group_id="O2" value="-78" lower_limit="-163" upper_limit="-29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Surfactant Protein D</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Surfactant Protein D</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="0" upper_limit="32"/>
                    <measurement group_id="O2" value="36" lower_limit="1" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma vonWillebrand Factor</title>
        <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma vonWillebrand Factor</title>
          <description>30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="-103" upper_limit="158"/>
                    <measurement group_id="O2" value="68" lower_limit="21" upper_limit="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Multiple Organ Dysfunction Score (MODS) During First 28 Days After Study Enrollment</title>
        <description>Full scale name is Multiple Organ Dysfunction Score (MODS), a scale measuring degree of organ dysfunction in critically ill patients.
Minimum score is 0 and maximum score is 24, with 0 indicating no organ failure and 24 indicating severe failure of multiple organs.</description>
        <time_frame>Throughout hospital stay</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Multiple Organ Dysfunction Score (MODS) During First 28 Days After Study Enrollment</title>
          <description>Full scale name is Multiple Organ Dysfunction Score (MODS), a scale measuring degree of organ dysfunction in critically ill patients.
Minimum score is 0 and maximum score is 24, with 0 indicating no organ failure and 24 indicating severe failure of multiple organs.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="3.1"/>
                    <measurement group_id="O2" value="8.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days During First 28 Days After Study Enrollment</title>
        <description>Ventilator-free days is a common outcome measure in critical care research. A ventilator-free day is a day that a participant is alive and not receiving mechanical ventilation during the first 28 days after s/he enrolled in the study.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days During First 28 Days After Study Enrollment</title>
          <description>Ventilator-free days is a common outcome measure in critical care research. A ventilator-free day is a day that a participant is alive and not receiving mechanical ventilation during the first 28 days after s/he enrolled in the study.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="10.3"/>
                    <measurement group_id="O2" value="13.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU-free Days During First 28 Days After Study Enrollment</title>
        <description>ICU-free days is a common outcome measure in critical care research. An ICU-free day is a day that a participant is alive and not in the intensive care unit (ICU) during the first 28 days after s/he enrolled in the study.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>ICU-free Days During First 28 Days After Study Enrollment</title>
          <description>ICU-free days is a common outcome measure in critical care research. An ICU-free day is a day that a participant is alive and not in the intensive care unit (ICU) during the first 28 days after s/he enrolled in the study.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="9.8"/>
                    <measurement group_id="O2" value="11.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>At end of hospital admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="18.3"/>
                    <measurement group_id="O2" value="27.6" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality</title>
        <time_frame>At end of hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>60-day Mortality</title>
        <time_frame>60 days from day of enrollment into study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>60-day Mortality</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-531" lower_limit="-1308" upper_limit="94"/>
                    <measurement group_id="O2" value="-298" lower_limit="-870" upper_limit="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Leukotriene B4</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Leukotriene B4</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="33"/>
                    <measurement group_id="O2" value="16" lower_limit="0" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Interleukin-6</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Interleukin-6</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52" lower_limit="-898" upper_limit="0"/>
                    <measurement group_id="O2" value="-198" lower_limit="-865" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Monocyte Chemotactic Protein-1</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Monocyte Chemotactic Protein-1</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-402" lower_limit="-1690" upper_limit="-41"/>
                    <measurement group_id="O2" value="-670" lower_limit="-1057" upper_limit="-151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BALF Neutrophil Count</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BALF Neutrophil Count</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL). Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units># of cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-48" upper_limit="8"/>
                    <measurement group_id="O2" value="-10" lower_limit="-56" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Interleukin-8</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Interleukin-8</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-17" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-15" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Leukotriene B4</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Leukotriene B4</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="3" upper_limit="40"/>
                    <measurement group_id="O2" value="6" lower_limit="-22" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Interleukin-6</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Interleukin-6</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83" lower_limit="-174" upper_limit="14"/>
                    <measurement group_id="O2" value="-78" lower_limit="-163" upper_limit="-29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Surfactant Protein D</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Surfactant Protein D</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="-12" upper_limit="78"/>
                    <measurement group_id="O2" value="17" lower_limit="-36" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma vonWillebrand Factor</title>
        <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
        <time_frame>Days 1 and 9</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Fish Oil</title>
            <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
          </group>
          <group group_id="O2">
            <title>Enteral Saline</title>
            <description>7.5cc 0.9% saline every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma vonWillebrand Factor</title>
          <description>15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g. mortality) were collected.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="-9" upper_limit="235"/>
                    <measurement group_id="O2" value="43" lower_limit="-21" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days from day of study enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enteral Fish Oil</title>
          <description>7.5cc of enteral fish oil every 6 hours equalling 9.75g EPA and 6.75g DHA daily</description>
        </group>
        <group group_id="E2">
          <title>Enteral Saline</title>
          <description>7.5cc 0.9% saline every 6 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Trombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation with rapid ventricular response</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PEA arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pericardial tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Right eye blindness after prolonged prone surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Fulminant liver failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nosocomial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent falls</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Delayed spinal cord contusion and injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure requiring renal replacement therapy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural and pericardial effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Critical hypoxemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspiration with reintubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme minor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Severe hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Total Infections</sub_title>
                <counts group_id="E1" events="51" subjects_affected="24" subjects_at_risk="41"/>
                <counts group_id="E2" events="50" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Renee Stapleton, MD PhD</name_or_title>
      <organization>University of Vermont</organization>
      <phone>802-656-7975</phone>
      <email>renee.stapleton@uvm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

